Kaiser L - Search Results

1

Use of protamine to augment adenovirus-mediated cancer gene therapy.

Lanuti M, Kouri CE, Force S, Chang M, Amin K, Xu K, Blair I, Kaiser L, Albelda S. Lanuti M, et al. Among authors: kaiser l. Gene Ther. 1999 Sep;6(9):1600-10. doi: 10.1038/sj.gt.3300987. Gene Ther. 1999. PMID: 10490770

2

Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy.

Odaka M, Wiewrodt R, DeLong P, Tanaka T, Zhang Y, Kaiser L, Albelda S. Odaka M, et al. Among authors: kaiser l. Mol Ther. 2002 Aug;6(2):210-8. doi: 10.1006/mthe.2002.0656. Mol Ther. 2002. PMID: 12161187 Free article.

3

Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.

Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, Force S, Chang M, Lanuti M, Black ME, Kaiser LR, Albelda SM. Wiewrodt R, et al. Cancer Gene Ther. 2003 May;10(5):353-64. doi: 10.1038/sj.cgt.7700589. Cancer Gene Ther. 2003. PMID: 12719705

4

Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling.

Singhal S, Amin KM, Kruklitis R, DeLong P, Friscia ME, Litzky LA, Putt ME, Kaiser LR, Albelda SM. Singhal S, et al. Cancer Biol Ther. 2003 May-Jun;2(3):291-8. doi: 10.4161/cbt.2.3.399. Cancer Biol Ther. 2003. PMID: 12878869 Free article.

5

Gene expression profiling of malignant mesothelioma.

Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J, Kucharczuk JC, Litzky LA, Johnson SW, Kaiser LR, Albelda SM. Singhal S, et al. Clin Cancer Res. 2003 Aug 1;9(8):3080-97. Clin Cancer Res. 2003. PMID: 12912960

6

Microarray data simulator for improved selection of differentially expressed genes.

Singhal S, Kyvernitis CG, Johnson SW, Kaiser LR, Liebman MN, Albelda SM. Singhal S, et al. Cancer Biol Ther. 2003 Jul-Aug;2(4):383-91. doi: 10.4161/cbt.2.4.431. Cancer Biol Ther. 2003. PMID: 14508110 Free article.

7

Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling.

Singhal S, Amin KM, Kruklitis R, Marshall MB, Kucharczuk JC, DeLong P, Litzky LA, Kaiser LR, Albelda SM. Singhal S, et al. Cancer Biol Ther. 2003 Sep-Oct;2(5):566-71. doi: 10.4161/cbt.2.5.514. Cancer Biol Ther. 2003. PMID: 14614329 Free article.

8

Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.

DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, Sterman DH, Albelda SM. DeLong P, et al. Cancer Res. 2003 Nov 15;63(22):7845-52. Cancer Res. 2003. PMID: 14633712

9

Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.

Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, Albelda SM. Kruklitis RJ, et al. J Thorac Cardiovasc Surg. 2004 Jan;127(1):123-30. doi: 10.1016/j.jtcvs.2003.08.034. J Thorac Cardiovasc Surg. 2004. PMID: 14752422 Free article.

10

Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.

Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, Albelda SM. Suzuki E, et al. Clin Cancer Res. 2004 Sep 1;10(17):5907-18. doi: 10.1158/1078-0432.CCR-03-0611. Clin Cancer Res. 2004. PMID: 15355924

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,574 results

Search Page

Filters